EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, AMGN:

18 Sep 2025
LAST:

275.8

CHANGE:
 1.12		OPEN:
274.7		HIGH:
276.5		ASK:
179.0		VOLUME:
3.32M
CHG(%):
0.41		PREV:
274.7		LOW:
274.0		BID:
175.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
18 Sep 25274.7276.5274.0275.83.32M
17 Sep 25274.1277.8273.0274.71.75M
16 Sep 25275.9277.6271.7273.12.16M
15 Sep 25276.1277.2271.6274.42.56M
12 Sep 25281.0282.9276.1276.42.14M
11 Sep 25278.5282.9278.0282.72.23M
10 Sep 25280.0280.3275.2278.52.15M
09 Sep 25279.5282.1278.8280.01.73M
08 Sep 25281.1282.4277.3280.22.45M
05 Sep 25279.8285.3279.0283.62.3M

COMPANY PROFILE

Name:
About:Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Sector:Healthcare
Address:One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
Website:https://www.amgen.com
CUSIP:031162100
CIK:0000318154
ISIN:US0311621009
FIGI:BBG000BBS2Y0
LEI:62QBXGPJ34PQ72Z12S66

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:24.15
DivYield:0.03
Div/Share:9.26
Price to Book:21.21
Price to Sales:4.56
EBITDA:16.148B
Shares:538.36M
Market Cap:148.496B

TECHNICAL INDICATORS

MA5:274.88
MA10:277.95
MA20:282.96
MA50:291.02
MA100:286.92
MA200:287.66
STO9:27.85
STO14:17.53
RSI14:36.02
WPR14:-81.23
MTM14:-11.88
ROC14:-0.04
ATR:5.10
Week High:282.94
Week Low:271.61
Month High:301.47
Month Low:271.61
Year High:339.17
Year Low:253.30
Volatility:19.53

RECENT SPLITS

Date Ratio
22 Nov 19992-1
01 Mar 19992-1
16 Aug 19952-1
11 Sep 19913-1
13 Aug 19902-1

RECENT DIVIDENDS

Date Amount
22 Aug 2025$2.38
16 May 2025$2.38
14 Feb 2025$2.38
18 Nov 2024$2.25
16 Aug 2024$2.25
16 May 2024$2.25
15 Feb 2024$2.25
16 Nov 2023$2.13
17 Aug 2023$2.13
17 May 2023$2.13